Effect of Intensive Statin Therapy on Clinical Outcomes Among Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy

Journal of the American College of Cardiology

Volumn 54, Issue 24, 2009, Pages 2290-2295

  Gibson, C Michael ^a   Pride, Yuri B ^a   Hochberg, Claudia P ^a   Sloan, Sarah ^a   Sabatine, Marc S ^a   Cannon, Christopher P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

acute coronary syndrome; percutaneous coronary intervention; pleiotropic; statin

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; C REACTIVE PROTEIN; CLOPIDOGREL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; TRIACYLGLYCEROL; WARFARIN;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; FEMALE; FOLLOW UP; HEART INFARCTION; HOSPITALIZATION; HUMAN; INCIDENCE; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; STROKE; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOVASCULAR DISEASES; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PRAVASTATIN; PYRROLES;

EID: 70549111032     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.09.010     Document Type: Article

References (23)

1. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
2. Schwartz G.G., Olsson A.G., Ezekowitz M.D., et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285 (2001) 1711-1718
3. de Lemos J.A., Blazing M.A., Wiviott S.D., et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes. JAMA 292 (2004) 1307-1316
4. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
5. Calabro P., and Yeh E.T. The pleiotropic effects of statins. Curr Opin Cardiol 20 (2005) 541-546
6. Ray K.K., and Cannon C.P. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol 46 (2005) 1425-1433
7. Almuti K., Rimawi R., Spevack D., and Ostfeld R.J. Effects of statins beyond lipid lowering: potential for clinical benefits. Int J Cardiol 109 (2006) 7-15
8. Cannon C.P., McCabe C.H., Belder R., Breen J., and Braunwald E. Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial. Am J Cardiol 89 (2002) 860-861
9. Wiviott S.D., de Lemos J.A., Cannon C.P., et al. A tale of two trials: a comparison of the post-acute coronary syndrome lipid trials A to Z and PROVE IT-TIMI 22. Circulation 113 (2006) 1406-1414
10. Serruys P.W., de Feyter P., Macaya C., et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 287 (2002) 3215-3222
11. Johnson C, Waters DD, DeMicco DA, et al. Comparison of effectiveness of atorvastatin 10 mg versus 80 mg in reducing major cardiovascular events and repeat revascularization in patients with previous percutaneous coronary intervention (post hoc analysis of the Treating to New Targets [TNT] study). 2008;102:1312-7.
12. King III S.B., Smith Jr. S.C., Hirshfeld Jr. J.W., et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (2007 Writing Group to Review New Evidence and Update the 2005 ACC/AHA/SCAI Guideline Update for Percutaneous Coronary Intervention). J Am Coll Cardiol 51 (2008) 172-209
13. Ray K.K., Cannon C.P., and Ganz P. Beyond lipid lowering: what have we learned about the benefits of statins from the acute coronary syndromes trials?. Am J Cardiol 98 (2006) S18-S25
14. Ray K.K., and Cannon C.P. Early time to benefit with intensive statin treatment: could it be the pleiotropic effects?. Am J Cardiol 96 (2005) 54F-60F
15. Ballantyne C.M., Raichlen J.S., Nicholls S.J., et al. Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. Circulation 117 (2008) 2458-2466
16. Crouse III J.R., Raichlen J.S., Riley W.A., et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR trial. JAMA 297 (2007) 1344-1353
17. Nissen S.E., Nicholls S.J., Sipahi I., et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295 (2006) 1556-1565
18. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291 (2004) 1071-1080
19. Okazaki S., Yokoyama T., Miyauchi K., et al. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH study. Circulation 110 (2004) 1061-1068
20. Libby P., and Sasiela W. Plaque stabilization: can we turn theory into evidence?. Am J Cardiol 98 (2006) S26-S33
21. Aikawa M., Rabkin E., Sugiyama S., et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 103 (2001) 276-283
22. Shirai H., Autieri M., and Eguchi S. Small GTP-binding proteins and mitogen-activated protein kinases as promising therapeutic targets of vascular remodeling. Curr Opin Nephrol Hypertens 16 (2007) 111-115
23. Rolfe B.E., Worth N.F., World C.J., Campbell J.H., and Campbell G.R. Rho and vascular disease. Atherosclerosis 183 (2005) 1-16